Research Progress of Metabolomics in Hematological Malignancies --Review.
10.19746/j.cnki.issn.1009-2137.2025.02.047
- Author:
Han-Ke WANG
1
;
Jun GUAN
2
;
Lin ZHOU
3
Author Information
1. Department of Blood Transfusion, The Affiliated Hospital of Yangzhou University, Yangzhou 225009, Jiangsu Province, China.
2. Department of Hematology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou 225009, Jiangsu Province, China.
3. Department of Laboratory Medicine, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou 225009, Jiangsu Province, China.
- Publication Type:English Abstract
- Keywords:
metabolomics;
hematological malignancy;
biomarker;
therapeutic strategy;
research progress
- MeSH:
Humans;
Metabolomics/methods*;
Hematologic Neoplasms/diagnosis*;
Biomarkers, Tumor
- From:
Journal of Experimental Hematology
2025;33(2):616-620
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, as a new omics field, metabolomics has been proved to be of great value in the study of the mechanism of occurrence and progression, the screening of new biomarkers and the development of novel therapeutic strategies in many diseases including tumors. In this review, we briefly summarized the research methods and techniques of metabolomics, and focused on the latest research progress of metabolomics in the pathogenesis of hematological malignancies represented by leukemia, lymphoma and multiple myeloma, screening of biomarkers for diagnosis and prognosis, and development of new therapeutic strategies. This article proposes the limitations of metabolomics and future research strategies, and provides a new exploration direction for accurate diagnosis and treatment as well as prognosis evaluation of hematological malignancies.
